Википедија

Farmakokinetika — разлика између измена

Интерактиван преглед историје
← Старија изменаНовија измена →
Садржај обрисан Садржај додат
ВизуелноВикитекст
м -pages
Autobot (разговор | доприноси)
1.572.075 измена
м ref=harv; козметичке измене
Ред 4:
|ширина = 40%
}}
[[ImageДатотека:Gráfica Km.png|thumb|250px|Grafikon koji demonstrira [[Михаелис-Ментенина кинетика|Mihaelis-Menteninov kinetčki]] model odnosa između enzima i supstrata]]
 
Farmakokinetika opisuje kako telo deluje na specifični lek nakon doziranja putem mehanizama apsorpcije i distribucije, kao i hemijske promene supstane u telu (e.g. posredstvom metaboličkih enzima kao što su [[enzim]]i [[citohrom P450]] ili [[glukuronoziltransferaza]]), i efekte i puteve izlučivanja metabolita leka.<ref>-{Pharmacokinetics. (2006). In ''Mosby's Dictionary of Medicine, Nursing, & Health Professions''. Philadelphia, PA: Elsevier Health Sciences. Retrieved December 11, 2008, from http://www.credoreference.com/entry/6686418 }-</ref> Farmakokinetička svojstva leka mogu da budu uslovljena faktorima poput mesta administriranja i doze leka. Ti faktori mogu da utiču na brzinu apsorpcije.<ref>{{Cite book |author=Kathleen Knights; Bronwen Bryant |title=Pharmacology for Health Professionals |publisher=Elsevier |location=Amsterdam |year=2002 |pages= |isbn=0-7295-3664-5 |oclc= |doi= |accessdate=}}</ref> Farmakokinetika se često studira zajedno sa [[farmakodinamika|farmakodinamikom]].
 
== Reference ==
{{reflist|2}}
 
== Literatura ==
{{refbegin|2}}
* {{Cite book |ref= harv|editor = Horning MG, Mitchell J | title = Drug metabolism and drug toxicity | publisher = Raven Press | location = New York | year = 1984 | isbn = 0-89004-997-1 | chapter = Pharmacokinetics: Basic Principles and Its Use as a Tool in Drug Metabolism | chapterurl = http://bts.ucsf.edu/benet_lab/index.php?page=benet | author = Benet LZ | ref = harv}}
* {{Cite book |ref= harv|author=Kathleen Knights; Bronwen Bryant |title=Pharmacology for Health Professionals |publisher=Elsevier |location=Amsterdam |year=2002 |isbn=0-7295-3664-5 |oclc= |doi= |accessdate=| ref = harv}}
* Alberts et al., ''Introducción a la Biología Celular'', pág. 375-376, 2ª edición, Ed. Médica Panamericana
* Alberts et al., ''Biología Molecular de la célula'', pág. 595, 4ª edición, Ed. Omega
* Armijo JA. 2003. ''Farmacocinética: Absorción, Distribución y Eliminación de los Fármacos''. En: Flórez J, Armijo JA, Mediavilla A, ''Farmacología Humana'', 4ta edición. Masson. Barcelona. pp: 51-79.
* Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW., ''Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection'', Curr Top Med Chem. 2005;5(11):1033-8.
* Beal, S.; Sheiner L.B. "The NONMEM System". The American Statistician 34: 118–9. (1980). doi:10.2307/2684123.
* Cooper, ''La célula'', pág 470-471, 2ª edición, Ed. Marbán
* Covey TR, Lee ED, Henion JD "High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples". Anal. Chem. 58: 2453–60. (October 1986). doi:10.1021/ac00125a022. PMID 3789400.
* Covey TR, JB Crowther, EA Dewey, JD Henion "Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids". Anal. Chem. 57 (2): 474–81. (February 1985). doi:10.1021/ac50001a036. PMID 3977076.
* Danielson P (2002). "The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans". Curr Drug Metab 3 (6): 561-97. PMID 12369887.
* Davies K (1995). "Oxidative stress: the paradox of aerobic life". Biochem Soc Symp 61: 1-31. PMID 8660387.
* Devlin, T. M. 2004. ''Bioquímica'', 4ª edición. Reverté, Barcelona. ISBN 84-291-7208-4
* Galvão T, Mohn W, de Lorenzo V (2005). "Exploring the microbial biodegradation and biotransformation gene pool". Trends Biotechnol 23 (10): 497-506. PMID 16125262.
* Hsieh Y, Korfmacher WA "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism 7 (5): 479–89.(June 2006). PMID 16787157. Disponible en [http://www.bentham-direct.org/pages/content.php?CDM/2006/00000007/00000005/0004F.SGM.]
* Janssen D, Dinkla I, Poelarends G, Terpstra P (2005). "Bacterial degradation of xenobiotic compounds: evolution and distribution of novel enzyme activities". Environ Microbiol 7 (12): 1868-82. PMID 16309386.
* Kathleen Knights; Bronwen Bryant (2002). ''Pharmacology for Health Professionals''. Amsterdam: Elsevier. ISBN 0-7295-3664-5.
Ред 35:
* Sheehan D, Meade G, Foley V, Dowd C (2001). "Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily". Biochem J 360 (Pt 1): 1-16. PMID 11695986.
* Sheiner, L.B.; Beal, S.L., Rosenberg, B. Marathe, V.V. "Forecasting Individual Pharmacokinetics". Clin. Pharmacol. Ther. 26: 294–305. (1979). PMID 466923.
* Sheiner, L.B.; Rosenberg, B., Marathe, V.V. "Estimation of Population Characteristics of Pharmacokinetic Parameters from Routine Clinical Data". J. Pharmacokin. Biopharm. 5: 445–79. 1.997 doi:10.1007/BF01061728.
* Sies H (1997). "Oxidative stress: oxidants and antioxidants". Exp Physiol 82 (2): 291-5. PMID 9129943.
* Singh SS., ''Preclinical pharmacokinetics: an approach towards safer and efficacious drugs'', Curr Drug Metab. 2006 Feb;7(2):165-82.
Преузето из „https://sr.wikipedia.org/wiki/Farmakokinetika”